Solu Therapeutics to Present Two Abstracts at ASH
Initial Phase 1 data on STX-0712 in chronic myelomonocytic leukemia and preclinical data on STX-0640 will be presented at the 2026 ASH Annual Meeting.
Updated on Nov. 4, 2026 in Cancer
Solu Therapeutics has had two abstracts selected for oral presentation at the 68th American Society of Hematology Annual Meeting in New Orleans, scheduled for December 12-15, 2026. The presentations include initial results from a first-in-human Phase 1 study of STX-0712 in chronic myelomonocytic leukemia and new preclinical data on STX-0640.
Why it matters
The presentations give the medical community an early look at two investigational therapies designed to eliminate disease-driving cells in cancer and immunology. The Phase 1 CMML data will be among the first clinical readouts for the company's CyTAC platform.
The company has two abstracts selected for oral presentation, with STX-0712 holding Fast Track Designation from the U.S. Food and Drug Administration. Clinical outcome data from the STX-0712 Phase 1 study were not included in the announcement and remain to be presented.
The players
Solu Therapeutics
A biotechnology company developing therapies that eliminate disease-driving cells in cancer and immunology, using its exclusively GSK-licensed CyTAC platform.
American Society of Hematology
A professional organization of hematologists whose annual meeting is among the largest venues for presenting blood disease research.
U.S. Food and Drug Administration
The federal agency that granted Fast Track Designation to STX-0712, a designation intended to speed development of drugs treating serious conditions.
The details
The STX-0712 presentation will cover initial results from a first-in-human study in patients with chronic myelomonocytic leukemia, an investigational Cytotoxicity Targeting Chimera that selectively eliminates CCR2-positive cells. The STX-0640 presentation will report preclinical data on a potential first-in-class mast cell depletor for systemic mastocytosis and immuno-dermatologic diseases.
Timeline
December 12-15, 2026: 68th ASH Annual Meeting in New Orleans, Louisiana.
December 13, 2026 at 9:30 AM CT: Oral presentation of STX-0712 CMML Phase 1 data.
December 13, 2026 at 5:30 PM CT: Oral presentation of STX-0640 preclinical data.
Big Picture
STX-0712's Fast Track Designation from the FDA places the candidate within the agency's expedited pathway for serious conditions. The ASH presentation adds early clinical data to that regulatory standing in a disease area with limited options.
Patients with chronic myelomonocytic leukemia and related blood cancers will not have access to STX-0712 from these presentations alone, since the data is from an early Phase 1 study. The results will help clinicians and patients understand the investigational approach as development continues.
The takeaway
Early clinical readouts at ASH are often the first public signal of whether a new mechanism is working in patients. Readers following CMML and mastocytosis research should watch the December 13 presentations for the first efficacy and safety data.
What happens next
The STX-0712 and STX-0640 oral presentations are scheduled for December 13, 2026 at ASH in New Orleans.
Further reading
Explore more Cancer research and treatment developments.
